D
Derek E. Smith
Researcher at University of Colorado Denver
Publications - 31
Citations - 1073
Derek E. Smith is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Lung cancer & KRAS. The author has an hindex of 13, co-authored 31 publications receiving 608 citations. Previous affiliations of Derek E. Smith include Anschutz Medical Campus & Colorado School of Public Health.
Papers
More filters
Journal ArticleDOI
Ecology under lake ice
Stephanie E. Hampton,Aaron W. E. Galloway,Stephen M. Powers,Ted Ozersky,Kara H. Woo,Ryan D. Batt,Stephanie G. Labou,Catherine M. O'Reilly,Sapna Sharma,Noah R. Lottig,Emily H. Stanley,Rebecca L. North,Jason D. Stockwell,Rita Adrian,Gesa A. Weyhenmeyer,Lauri Arvola,Helen M. Baulch,Isabella Bertani,Larry L. Bowman,Cayelan C. Carey,Jordi Catalan,William Colom-Montero,Leah M. Domine,Marisol Felip,Ignacio Granados,Corinna Gries,Hans-Peter Grossart,Hans-Peter Grossart,Juta Haberman,Marina Haldna,Brian Hayden,Scott N. Higgins,Jeffrey C. Jolley,Kimmo K. Kahilainen,Enn Kaup,Michael J. Kehoe,Sally Macintyre,Anson W. Mackay,Heather L. Mariash,Robert Michael L. McKay,Brigitte Nixdorf,Peeter Nõges,Tiina Nõges,Michelle E. Palmer,Donald C. Pierson,David M. Post,Matthew J. Pruett,Milla Rautio,Jordan S. Read,Sarah Roberts,Jacqueline Rücker,Steven Sadro,Eugene A. Silow,Derek E. Smith,Robert W. Sterner,George E. A. Swann,Maxim A. Timofeyev,Manuel Toro,Michael R. Twiss,Richard J. Vogt,Susan B. Watson,Erika J. Whiteford,Marguerite A. Xenopoulos +62 more
TL;DR: This is the first global quantitative synthesis on under-ice lake ecology, including 36 abiotic and biotic variables from 42 research groups and 101 lakes, examining seasonal differences and connections as well as how seasonal differences vary with geophysical factors.
Journal ArticleDOI
The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Tejas Patil,Derek E. Smith,Paul A. Bunn,Dara L. Aisner,Anh T. Le,Mark Hancock,William T. Purcell,Daniel W. Bowles,D. Ross Camidge,Robert C. Doebele +9 more
TL;DR: The CNS is a common first site of progression in ROS1‐positive patients who are taking crizotinib, and the importance of developing CNS‐penetrant tyrosine kinase inhibitors for patients with ROS1-positive NSCLC is reinforced.
Journal ArticleDOI
Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study.
Chad G. Rusthoven,Masaaki Yamamoto,Denise Bernhardt,Derek E. Smith,Dexiang Gao,Toru Serizawa,Shoji Yomo,Hitoshi Aiyama,Yoshinori Higuchi,Takashi Shuto,Atsuya Akabane,Yasunori Sato,Ajay Niranjan,Andrew Faramand,L. Dade Lunsford,James McInerney,Leonard Tuanquin,Brad E. Zacharia,Veronica Chiang,Charu Singh,James B. Yu,Steve Braunstein,David Mathieu,Charles J Touchette,Cheng-Chia Lee,Huai-Che Yang,Ayal A. Aizer,Daniel N. Cagney,Michael D. Chan,Douglas Kondziolka,Kenneth E. Bernstein,Joshua S. Silverman,Inga S. Grills,Zaid A. Siddiqui,Justin C. Yuan,Jason P. Sheehan,Diogo Cordeiro,Kename Nosaki,Takahashi Seto,Christopher P Deibert,Vivek Verma,Samuel E. Day,Lia M. Halasz,Ronald E Warnick,Daniel M. Trifiletti,Joshua D. Palmer,Albert Attia,Benjamin Li,Christopher P. Cifarelli,Paul D. Brown,John A. Vargo,John A. Vargo,Stephanie E. Combs,Kerstin A. Kessel,Stefan Rieken,Samir Patel,Matthias Guckenberger,Nicolaus Andratschke,Brian D. Kavanagh,Tyler P. Robin +59 more
TL;DR: Results of this study suggest that the primary trade-offs associated with SRS without WBRT, including a shorter TTCP without a decrease in overall survival, are similar to those observed in settings in which SRS is already established.
Journal ArticleDOI
Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.
Jose M. Pacheco,Dexiang Gao,Dexiang Gao,Derek E. Smith,Derek E. Smith,Thomas Purcell,Mark Hancock,Paul A. Bunn,Tyler P. Robin,Arthur K. Liu,Sana D. Karam,Laurie E. Gaspar,Brian D. Kavanagh,Chad G. Rusthoven,Dara L. Aisner,Robert C. Doebele,D. Ross Camidge +16 more
TL;DR: Patients with stage IV ALK‐positive NSCLC can have prolonged OS, and each additional month of pemetrexed‐based therapy was associated with a 7% relative decrease in risk of death.
Journal ArticleDOI
IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients.
Richard P Tobin,Kimberly R. Jordan,Puja Kapoor,Eric Spongberg,Dana Davis,Victoria M. Vorwald,Kasey L. Couts,Dexiang Gao,Derek E. Smith,Jessica S W Borgers,Jessica S W Borgers,Steven E. Robinson,Carol M. Amato,Rene Gonzalez,Rene Gonzalez,Karl D. Lewis,Karl D. Lewis,William A. Robinson,William A. Robinson,Virginia F. Borges,Virginia F. Borges,Martin D. McCarter,Martin D. McCarter +22 more
TL;DR: Results indicate an important role for IL-6 and IL-8 in melanoma patients in which IL- 6 potentially expands peripheral MDSCs andIL-8 recruits these highly immunosuppressive cells to the tumor microenvironment.